Yahoo
NYSEArca - Nasdaq Real Time Price USD

Capital Group Growth ETF (CGGR)

46.60 +0.45 (+0.97%)
As of 3:09:30 PM EDT. Market Open.
Trade CGGR on Coinbase
Chart Range Bar
Loading chart for CGGR
  • Previous Close 46.15
  • Open 46.32
  • Bid 46.54 x 160000
  • Ask 46.55 x 190000
  • Day's Range 46.14 - 46.60
  • 52 Week Range 38.55 - 48.69
  • Volume 1,513,703
  • Avg. Volume 2,606,134
  • Net Assets 26.01B
  • NAV 46.14
  • PE Ratio (TTM) 25.94
  • Yield 0.15%
  • YTD Daily Total Return 3.34%
  • Beta (5Y Monthly) 1.29
  • Expense Ratio (net) 0.39%

The fund invests primarily in common stocks and seeks to invest in companies that appear to offer superior opportunities for growth of capital. It may invest up to 25% of its assets in common stocks and other securities of issuers domiciled outside the United States. The fund relies on the professional judgment of its investment adviser to make decisions about the fund’s portfolio investments. The basic investment philosophy of the investment adviser is to seek to invest in attractively valued companies that, in its opinion, represent good, long-term investment opportunities. It is non-diversified.

Capital Group

Fund Family

Large Growth

Fund Category

26.01B

Net Assets

2022-02-22

Inception Date

Performance Overview

View More

Trailing returns as of 10/23/2026. Category is Large Growth.

YTD Return

CGGR
3.34%
Category
2.85%

1-Year Return

CGGR
3.12%
Category
29.03%

3-Year Return

CGGR
24.24%
Category
23.49%

People Also Watch

Holdings

View More

Top 10 Holdings (40.63% of Total Assets)

Symbol Company % Assets
Meta Platforms, Inc. 6.60%
NVIDIA Corporation 4.99%
Microsoft Corporation 4.66%
Broadcom Inc. 4.42%
Tesla, Inc. 4.03%
Micron Technology, Inc. 3.87%
Alphabet Inc. 3.26%
Visa Inc. 3.14%
Alphabet Inc. 3.13%
Apple Inc. 2.54%

Sector Weightings

Research Reports

View More
  • Lowering target price to $118.00

    M/I HOMES INC has an Investment Rating of HOLD; a target price of $118.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

  • Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of the total revenue is generated in the United States.

  • Daily – Vickers Top Insider Picks for 09/11/2026

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Boston Scientific Earnings: Competitive Pressure Closing in on Key Growth Areas

    Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: